MET and papillary renal cell carcinoma: For example, tivantinib (also called ARQ197) and a dual inhibitor of c-MET/VEGFR2 (foretinib) were studied in phase I to II clinical trials in patients with papillary renal cell carcinoma and advanced hepatocellular carcinoma, respectively [24].